Asset Details
Do you wish to reserve the book?
Adverse effects of dorsogluteal intramuscular injection versus ventrogluteal intramuscular injection: A systematic review and meta‐analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adverse effects of dorsogluteal intramuscular injection versus ventrogluteal intramuscular injection: A systematic review and meta‐analysis
Do you wish to request the book?
Adverse effects of dorsogluteal intramuscular injection versus ventrogluteal intramuscular injection: A systematic review and meta‐analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adverse effects of dorsogluteal intramuscular injection versus ventrogluteal intramuscular injection: A systematic review and meta‐analysis
2023
Overview
Aims To determine adverse effects of ventrogluteal intramuscular injections versus dorsogluteal intramuscular injections. Design A systematic review and meta‐analysis. Methods MEDLINE, EMBASE, CINHAL, CENTRAL, LILACS(BVS), BDENF (BVS), WoS, IRCTP(WHO), ClinicalsTrials.gov and PROSPERO databases were searched with no restriction on year or language. Preferred Reporting items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were followed. Results A total of 1429 participants from 17 studies were included. The meta‐analysis found that ventrogluteal injection site had significant relation to lower pain in 9 studies (SMD = −0.63, 95% CI = −0.87, −0.39), bleeding in 4 studies (SMD = −3.46, 95% CI = −6.07, –0.86) and hematoma in 2 studies; after 48 h (SMD = −0.25, 95% CI = −0.39, −0.11), and after 72 h (SMD = −0.16, 95% CI = −0.26, –0.06), if it was compared with dorsogluteal site injection. No differences were found when comparing the possibility of intramuscular injections given into de subcutaneous tissue. In three studies, ventrogluteal site did not significantly reduce the risk of subcutaneous injection (OR 0,62, 95% CI = 0.16, 2.41).
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
